Tirzepatide
What is Tirzepatide?
GLP-2 T is a synthetic peptide‑based medication that functions as a first‑in‑class dual agonist of the glucose‑dependent insulinotropic polypeptide (GIP) and glucagon‑like peptide‑1 (GLP‑1) receptors, two naturally occurring incretin hormones involved in metabolic regulation. By engaging both GIP and GLP‑1 pathways, GLP-2 T enhances glucose‑dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and increases satiety, resulting in improved blood sugar control and reduced appetite. It is FDA‑approved for the treatment of type 2 diabetes and chronic weight management, and clinical research has shown substantial reductions in blood glucose levels and body weight compared with traditional single‑pathway therapies.
Potential Benefits Shown in Studies
- Supports significant weight loss through appetite suppression and delayed gastric emptying
- Improves blood sugar control by enhancing glucose-dependent insulin secretion
- Reduces fasting and post-meal glucose levels
- Lowers HbA1c more effectively than GLP-1 agonists alone
- Promotes greater satiety and reduced caloric intake
- May improve lipid profiles and cardiometabolic markers
- Combines dual incretin activity (GIP + GLP-1) for enhanced metabolic impact
- FDA-approved for type 2 diabetes and obesity-related weight management
Mechanisms of Action
- GLP-1 Receptor Agonism: Increases insulin secretion, reduces glucagon, slows gastric emptying, and promotes satiety
- GIP Receptor Agonism: Enhances insulin sensitivity and complements GLP-1 effects on energy balance
- Dual Incretin Effect: Combines GLP-1 and GIP pathways for amplified metabolic response
- Appetite & Satiety Regulation: Acts on the hypothalamus to reduce hunger and increase fullness
- Glycemic Control: Lowers both fasting and postprandial blood glucose by mimicking natural gut hormone responses
Research Highlights
Insulin Control
Studies have shown that GLP-2 T helps with people who have type 2 diabetes
Molecular Structure
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Lys-Lys-γGlu-2xC16 (palmitoyl) diacid
C₂₂₅H₃₄₁N₄₉O₆₅
4813 g/mol
- The first 20 amino acids are based on the native GIP sequence
- Modifications throughout the sequence improve GLP-1 receptor activity
- A C20 fatty diacid (two C16 palmitic acid chains) is attached via a γ‑glutamic acid (γGlu) linker to promote albumin binding and extend half-life
- The full molecule is 39 amino acids long, plus the lipidated tail